US12208167 — Coated tablets for pH-dependent release of benzgalantamine
Method of Use · Assigned to Alpha Cognition Inc · Expires 2044-02-26 · 18y remaining
What this patent protects
This patent protects a coated tablet formulation of benzgalantamine for pH-dependent release, intended for treating brain diseases with cognitive impairment and/or cholinergic deficit.
USPTO Abstract
The invention relates to a pharmaceutical composition in the form of a tablet, said tablet comprising a tablet core, wherein said core comprises benzgalantamine (ALPHA-1062) or salt thereof, and an enteric coating, wherein said enteric coating is configured for dissolution at pH 5.5 and above. Further the invention relates to the pharmaceutical composition for use in the treatment of a brain disease associated with cognitive impairment and/or with a cholinergic deficit. The invention further relates to a method for preparing the pharmaceutical composition.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-713 |
— | benzgalantamine-gluconate |
U-713 |
— | benzgalantamine-gluconate |
U-713 |
— | benzgalantamine-gluconate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.